Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

741
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
741

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-locus sequence typing and phylogenetics of Cryptococcus neoformans AD hybrids.

Fungal genetics and biology : FG & B·2023
Same author

Exogenous citric acid enhances drought tolerance in tobacco (Nicotiana tabacum).

Plant biology (Stuttgart, Germany)·2021
Same author

Belantamab mafodotin for the treatment of multiple myeloma.

Drugs of today (Barcelona, Spain : 1998)·2021
Same author

Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Association of low skeletal muscle mass with the presence of advanced colorectal neoplasm: integrative analysis using three skeletal muscle mass indices.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2020
Same author

Prognostic model for identifying candidates for hepatectomy among patients with hepatocellular carcinoma and hepatic vein invasion.

The British journal of surgery·2020

Related Experiment Video

Updated: Oct 18, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.6K

Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.

Q Lu1,2, H Huang1, S Tang1

  • 1Department of Hematology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China.

Drugs of Today (Barcelona, Spain : 1998)
|September 29, 2021
PubMed
Summary
This summary is machine-generated.

Tafasitamab, an anti-CD19 antibody, offers a new treatment option for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients. It shows promise when combined with lenalidomide for those ineligible for stem cell transplantation.

Keywords:
B-cell lymphomaCombination therapyFc-engineered anti-CD19 antibodiesHematological malignanciesLenalidomideMonoclonal antibodiesNon-Hodgkin's lymphomasTafasitamab

More Related Videos

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.4K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Related Experiment Videos

Last Updated: Oct 18, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.6K
Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.4K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is a prevalent B-cell malignancy.
  • R-CHOP therapy is standard first-line treatment but has limitations, with 30-40% of patients experiencing treatment failure.
  • Relapsed/refractory DLBCL (R/R DLBCL) presents significant therapeutic challenges, particularly in elderly populations.

Purpose of the Study:

  • To evaluate the pharmacodynamics, pharmacokinetics, mechanism of action, and clinical utility of tafasitamab for DLBCL treatment.
  • To assess tafasitamab's role in managing R/R DLBCL, especially in patients unsuitable for autologous stem cell transplantation (ASCT).
  • To compare the benefits and drawbacks of tafasitamab with other CD19-targeted therapies like chimeric antigen receptor T cells (CAR-T cells).

Main Methods:

  • Review of existing literature on tafasitamab's pharmacology and clinical trials.
  • Analysis of tafasitamab's mechanism of action as an anti-CD19 monoclonal antibody.
  • Comparative discussion of tafasitamab and CAR-T cell therapies in the context of R/R DLBCL.

Main Results:

  • Tafasitamab, an Fc-enhanced, humanized anti-CD19 antibody, has received FDA approval for R/R DLBCL treatment.
  • It is recommended in combination with lenalidomide for R/R DLBCL patients ineligible for ASCT.
  • Tafasitamab demonstrates safety and efficacy in treating DLBCL.

Conclusions:

  • Tafasitamab represents a significant advancement in treating R/R DLBCL, offering a new therapeutic avenue.
  • The combination of tafasitamab and lenalidomide provides a viable option for a challenging patient subgroup.
  • Further evaluation of tafasitamab and comparison with CAR-T cells are crucial for optimizing DLBCL management.